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Abstract: Aldosterone (Aldo), when overproduced, is a cardiotoxic hormone underlying heart failure
and hypertension. Aldo exerts damaging effects via the mineralocorticoid receptor (MR) but also
activates the antiapoptotic G protein-coupled estrogen receptor (GPER) in the heart. G protein-coupled
receptor (GPCR)-kinase (GRK)-2 and -5 are the most abundant cardiac GRKs and phosphorylate
GPCRs as well as non-GPCR substrates. Herein, we investigated whether they phosphorylate
and regulate cardiac MR and GPER. To this end, we used the cardiomyocyte cell line H9c2
and adult rat ventricular myocytes (ARVMs), in which we manipulated GRK5 protein levels
via clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 and GRK2 activity
via pharmacological inhibition. We report that GRK5 phosphorylates and inhibits the cardiac MR
whereas GRK2 phosphorylates and desensitizes GPER. In H9c2 cardiomyocytes, GRK5 interacts
with and phosphorylates the MR upon β2-adrenergic receptor (AR) activation. In contrast, GRK2
opposes agonist-activated GPER signaling. Importantly, GRK5-dependent MR phosphorylation of
the MR inhibits transcriptional activity, since aldosterone-induced gene transcription is markedly
suppressed in GRK5-overexpressing cardiomyocytes. Conversely, GRK5 gene deletion augments
cardiac MR transcriptional activity. β2AR-stimulated GRK5 phosphorylates and inhibits the MR
also in ARVMs. Additionally, GRK5 is necessary for the protective effects of the MR antagonist
drug eplerenone against Aldo-induced apoptosis and oxidative stress in ARVMs. In conclusion,
GRK5 blocks the cardiotoxic MR-dependent effects of Aldo in the heart, whereas GRK2 may hinder
beneficial effects of Aldo through GPER. Thus, cardiac GRK5 stimulation (e.g., via β2AR activation)
might be of therapeutic value for heart disease treatment via boosting the efficacy of MR antagonists
against Aldo-mediated cardiac injury.
Keywords: aldosterone; cardiac myocyte; G protein-coupled receptor kinase; G protein-coupled
estrogen receptor; mineralocorticoid receptor; signal transduction
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1. Introduction
Aldosterone (Aldo) is among the hormones for which levels are elevated and contributes
significantly to the pathogenesis and morbidity/mortality of heart disease, including hypertension and
chronic heart failure (CHF) [1]. Most of its cardiotoxic effects are mediated by the mineralocorticoid
receptor (MR), a transcription factor expressed in various tissues including the heart [2]. However,
Aldo exerts MR-independent (“non-genomic”) actions, a great deal of which are through activation of
the G protein-coupled receptor 30 (GPR30) or G protein-coupled estrogen receptor (GPER), a plasma
membrane G protein-coupled receptor (GPCR) [3]. Most of the pathophysiological effects of Aldo in
the heart and vessels, which can cause essential hypertension and trigger cardiac hypertrophy, fibrosis,
and adverse remodeling, are thought to result from MR activation, whereas several studies suggest that
GPER activation may actually be beneficial in the myocardium, partly due to activation of antiapoptotic
mediators, such as Epidermal Growth Factor Receptor (EGFR) and extracellular signal-regulated kinase
(ERK)1/2 [2–7]).
Most GPCRs undergo functional desensitization due to phosphorylation by GPCR-kinases (GRKs),
a Ser/Thr protein kinase family, followed by binding of βarrestins which uncouple the receptor from its
cognate G proteins [8]. GRK2 and -5 are the most abundant GRKs in the heart and are also known to
phosphorylate non-GPCR substrates [9,10]. The MR is known to be phosphorylated at various Ser/Thr
residues, including Ser-843 of the ligand-binding domain and Ser-601 of the N-terminal domain [11].
These phosphorylating events occur in the cytoplasm, and some of them result in MR inhibition either
via direct repression of transcriptional activity (e.g., the Ser-843 phosphorylation) or via cytosolic
retention, i.e., blockade of nuclear translocation (e.g., the Ser-601 phosphorylation) [11]. Herein, we
sought to investigate the potential involvement of GRK2 and -5 in the regulation of cardiac Aldo
signaling via the MR and/or GPER.
2. Results
2.1. β2AR-Activated GRK5 but Not GRK2 and Interacts with the MR in H9c2 Cardiomyocytes
Via co-immunoprecipitation (co-IP) experiments in cultured H9c2 cardiomyocytes,
which endogenously express both β1- and β2-adrenergic receptors (ARs) [12] as well as the MR and
GPER [13,14], we uncovered that GRK5 interacts with the MR constitutively and that this interaction
is significantly boosted by β2AR activation with formoterol (Figure 1A,B). Of note, the non-subtype
selective βAR agonist isoproterenol did not affect appreciably the GRK5–MR interaction (Figure 1A,B),
suggesting that the β1AR might somehow compete with and offset the β2AR-mediated induction of
this interaction in H9c2 cardiomyocytes. In contrast to GRK5, no GRK2 interaction with the MR could
be detected under any treatment conditions (including constitutively, i.e., no cell treatment) in H9c2
cardiomyocytes (Figure 1A).
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Figure 1. Interaction of G protein-coupled receptor (GPCR)-kinase (GRK)-5 but not GRK2 with the 
mineralocorticoid receptor (MR) in cardiac myocytes and the role of β-adrenergic receptors (ARs): (A) 
Immunoblotting for GRK2 and GRK5 in MR immunoprecipitates from H9c2 cardiomyocyte extracts 
prepared after 15-min-long treatments with vehicle (dimethylsulfoxide—DMSO, Veh), 100 nM G1, 100 nM 
aldosterone (Ald), 10 µM isoproterenol (Iso), or 10 µM formoterol (For). Blots for MR are also shown to 
confirm equal amounts of receptor immunoprecipitated. IP: immunoprecipitation; IB: Immunoblotting; 
IgG: Negative control for the co-IP (general rabbit IgG was used in the IP instead of an anti-MR antibody). 
Representative blots are shown in (A) and the relative densitometric quantitation of five independent 
experiments done in duplicate is shown in (B). * p < 0.05, vs. any other treatment; n = 5. 
2.2. GRK2 but Not GRK5 Binds to and Desensitizes Agonist-Activated GPER in H9c2 Cardiomyocytes 
Next, we checked for potential interactions of GRK2 and -5 with the plasma membrane-residing 
GPER in H9c2 myocytes. Co-IP experiments with GPER and the two GRKs revealed the exact inverse 
picture from the one with the MR above (Figure 1). Specifically, GRK2 was found to interact with 
GPER in an agonist-dependent manner (i.e., in response to either Aldo or the GPER synthetic agonist 
G1), whereas no GRK5 interaction with GPER could be detected in the presence or absence of either 
GPER agonist (Figure 2A). 
Given that GRK2 interacts only with agonist-activated GPER, which is a GPCR, we speculated 
that the GRK2–GPER interaction probably results in classic desensitization of the receptor, i.e., G 
protein uncoupling. Indeed, this was confirmed via guanosine 5’-O-[gamma-thio]triphosphate, 
(GTPγS) experiments performed with GPER pretreated with G1 in the presence or absence of the 
known GRK2-specific small molecule inhibitor Cmpd101 [15] (Figure 2B). GRK2 blockade with 
Cmpd101 significantly increased the extent of G1-induced GTPγS binding of the G1-pretreated GPER 
(Figure 2B), a strong indication that GRK2 causes functional desensitization of GPER. 
Figure 1. Interaction of G protein-coupled receptor (GPCR)-kinase (GRK)-5 but not GRK2 with the
mineralocorticoid receptor (MR) in cardiac myocytes and the role of β-adrenergic receptors (ARs):
(A) Immunoblotting for GRK2 and GRK5 in MR immunoprecipitates from H9c2 cardiomyocyte extracts
prepared after 15-min-long treatments with vehicle (dim thylsulfoxide—DMSO, Veh), 100 nM G1,
100 nM aldosterone (Ald), 10 µM isoproter nol (Iso), or 10 µM formoterol (For). Blots for MR are
also show to confirm equal amounts of receptor immunoprecipitated IP: immunoprecipitation; IB:
Immunoblotting; IgG: Negative control for the co-IP (general rabbit IgG was used i the P instead f a
anti-MR antibody). Representative blots are shown in (A) and the relative densitometric quantitation
of five independent experiments done in duplicate is shown in (B). * p < 0.05, vs. any other treatment;
n = 5.
2. . GRK2 but Not GRK5 Binds to and Desensitizes Agonist-Activated GPER in H9c2 Cardiomyocytes
Next, we checked for potential interactions of GRK2 and -5 with the plasma membrane-residing
GPER in H9c2 myocytes. Co-IP experiments with GPER and the two GRKs revealed the xact inverse
picture from the one with the MR above (Figure 1). Specifically, GRK2 was found to interact with
GPER in an agonist-dependent man er (i.e., in response to either Aldo r the GPER synthetic agonist
G1), whereas no GRK5 interaction with GPER could be detected in the presence or absence of either
GPER agonist (Figure 2A).
Given that GRK2 interacts only with agonist-activated GPER, which is a GPCR, we speculated that
the GRK2–GPER interaction probably results in cla sic desensitization of the receptor, i.e., G prot in
unc upling. Indeed, this was confirmed via guanosine 5’-O-[gamma-thio]triphosphate, (GTPγS)
experiments erformed with GPER pretreated with G1 in the presenc o absence of the kn wn
GRK2-specific small molecule inhibitor Cmpd101 [15] (Figure 2B). GRK2 blockade with Cmpd101
significantly increased the extent of G1-induced TPγS bin ing of the G1-pretreat d GPER (Figure 2B),
a strong indic tion that GRK2 causes functional desensi ization of GPER.
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Figure 2. GRK2 but not GRK5 desensitizes G protein-coupled estrogen receptor (GPER) in cardiac 
myocytes. (A) Immunoblotting for GRK2 and GRK5 in GPER immunoprecipitates from H9c2 
cardiomyocyte extracts prepared after 15-min-long treatments with vehicle (DMSO, Veh), 100 nM G1, 
or 100 nM aldosterone (Ald). Blots for GPER are also shown to confirm equal amounts of receptor 
immunoprecipitated. IP: immunoprecipitation; IB: Immunoblotting; IgG: Negative control for the co-IP 
(general rabbit IgG was used in the IP instead of an anti-GPER antibody). (B) Total GTPγS binding to 
measure G1-induced GPER desensitization in H9c2 cardioymyocytes: Cells were treated with 100 nM 
G1 for 15 min following a 30-min-long pretreatment with either 100 nM G1 alone (G1-pretreated) or 100 
nM G1 in the presence of 30 µM Cmpd101 (Cmpd101 + G1-pretreated). *, p < 0.05; n = 5 independent 
experiments performed in triplicate. 
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Conversely, in cardiomyocytes lacking GRK5 due to lentivirus-mediated clustered regularly 
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transfected cells (Figure 3A,B). Interestingly, the MR phosphorylation detected in these experiments 
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interaction above (Figure 1). Finally, in vitro kinase assay experiments with human recombinant 
GRK5 and resin-immobilized human recombinant MR protein confirmed that the MR is directly 
phosphorylated by GRK5. Taken together, these results strongly suggest that the cardiac MR is a 
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Next, we examined the impact of GRK5-induced phosphorylation on the transcriptional activity 
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Figure 2. GRK2 but not GRK5 desensitizes G protein-coupled estrogen receptor (GPER) in cardiac
myocytes. (A) Im unoblotting for GRK2 and GRK5 in GPER i munoprecipitates from H9c2
cardiomyoc te extracts prepared after i -long treatments with vehicle (DMSO, Veh), 100 nM G1,
or 100 nM aldosterone (Ald). Blots for re also shown to confirm equal amounts of receptor
immunoprecipitated. IP: immunoprecipitation; IB: Immunoblotting; IgG: Negative control for the co-IP
(general rabbit IgG was used in the IP instead of an anti-GPER antibody). (B) Total GTPγS binding to
measure G1-induced GPER desensitization in H9c2 cardioymyocytes: Cells were treated with 100 nM
G1 for 15 min following a 30-min-long pretreatment with either 100 nM G1 alone (G1-pretreated)
or 100 nM G1 in the presence of 30 µM Cmpd101 (Cmpd101 + G1-pretreated). *, p < 0.05; n = 5
independent experiments performed in triplicate.
2.3. GRK5 Phosphorylates the MR, Inhibiting Its Transcriptional Activity in H9c2 Cardiomyocytes
We postulated that t e MR is a phosphorylation substrate for the Ser/Thr kinase GRK5. I deed,
there are several Ser/Thr residues located within all three functional domains (N-terminal domain
(NTD); central DNA-binding domain (DBD); and C-terminal ligand-binding domain (LBD)) of
the human MR protein (UniProtKB #P08235) [11] that are excellent substrates for GRK5-mediated
phosphorylation, as predicted by the NetPhos 2.0 Protein Phosphorylation Prediction Server software
(http://www.cbs.dtu.dk/services/NetPhos/np.html) [16]. Using a general anti-phosphoSer antibody
to measure the phosphorylated Ser content of immunoprecipitated MR in H9c2 cardiomyocytes
overexpressing GRK5 (via transfection with a lentivirus encoding for full length GRK5), we found that
the ph spho-Ser content f the MR was markedly augmented in GRK5-overexper sing cardiomyocytes
compared to control, mock (empty vector) virus-transfected cells (Figure 3A,B). Convers ly, in
cardiomyocytes lacking GRK5 due to lentivirus-mediated clustered regularly interspaced short
palindromic repeats (CRISPR)/Cas9 rat GRK5 gene deletion (Figure 3C), the phospho-Ser content of the
MR was strikingly diminished compared to control, mock CRISPR virus-transfected cells (Figure 3A,B).
Interestingly, the MR phosphorylation detected in these experiments was unaffected by the presence or
absence of Aldo (Figure 3A,B), similarly to the GRK5-MR interaction above (Figure 1). Finally, in vitro
kinase assay experiments with human recombinant GRK5 and resin-immobilized human recombinant
MR protein confirmed that the MR is directly phosphorylated by GRK5. Take together, these results
strongly suggest that the cardia MR is a phosphorylation substrate f GRK5.
Next, we examined the impact of GRK5-induced phosphorylati n on the transcriptional activity
of the MR in H9c2 cardiomyocytes. Employing the luciferase gene reporter assay in cells expressing the
luciferase gene under the influence of the MR gene (NR3C2) promoter, we found that Aldo-dependent
MR transcriptional activity was significantly enhanced in GRK5-depleted cardiomyocytes but
virtually abrogated in GRK5-overexpressing H9c2 cardiomyocytes (Figure 3D). This strongly indicates
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that GRK5-induced phosphorylation of the cardiac MR leads to inhibition of its Aldo-dependent
transcriptional activity.
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CNCV; n = 5. (C) Immunoblotting for GRK5 in extracts from H9c2 cardiomyocytes, transfected with 
empty vector/mock lentivirus (EV), full-length wild-type GRK5-encoding lentivirus to overexpress 
GRK5 (OE), CRISPR negative control (mock) lentivirus (CNCV), or CRISPR rat GRK5-specific 
lentivirus to knockout GRK5 (KO). Total protein extracts were prepared 48 h post-infection and then 
separated on a 4%–20% SDS-PAGE gel. A representative blot is shown, including glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as loading control, of five independent experiments performed 
in duplicate, confirming GRK5 overexpression and deletion in OE and KO cells, respectively. (D) 
Transcriptional activity of the MR in response to various concentrations of Aldo in H9c2 
cardiomyocytes overexpressing GRK5 (GRK5-OE) or having GRK5 genetically deleted (GRK5-KO). 
EV: Empty vector; CNCV: CRISPR negative control virus; * p < 0.05, between GRK5-KO and EV or 
CNCV; ** p < 0.05, between GRK5-OE and EV or CNCV; n = 5 independent measurements with 
triplicate samples per Aldo concentration. 
2.4. GRK5 Protects Against Aldo-Induced Apoptosis/Oxidative Stress and Is Necessary for Eplerenone’s 
Inhibitory Actions in ARVMs 
Since the cardiotoxic effects of Aldo, including apoptosis, oxidative stress, fibrosis, and 
inflammation, are almost exclusively mediated by the MR [2,5], the finding that GRK5 
phosphorylates and inhibits the cardiac MR hints at potential cardioprotective effects of this kinase. 
Thus, we measured the effects of GRK5 on Aldo signaling also in cultured adult rat ventricular 
myocytes (ARVMs), a bona fide cardiomyocyte cell system even more physiologically relevant than 
H9c2 myocytes. We also tested the effects of GRK5 in ARVMs in the presence or absence of the known 
Figure 3. GRK5 phosphorylates and inhibits the MR in cardiac myocytes. (A) Western blotting for
phosphoserine content of immunoprecipitated MR in response to 100 nM aldosterone (Aldo) stimulation
for 15 min or vehicle (DMSO) in GRK5-overexpressing (GRK5-OE) or control, mock lentivirus-infected
(EV) H9c2 myocyte lysates or in lysates from myocytes that had GRK5 genetically deleted (GRK5-KO)
and their respective control cells (CNCV, CRISPR (Clustered regularly interspaced short palindromic
repeats) negative control virus). IP: immunoprecipitation; IB: Immunoblotting. Representative blots are
shown in (A) and th relative densitometric quant t ion of five independent experiments performed
in duplicate is shown in (B). * p < 0.05, vs. EV; # p < 0.05, vs. CNCV; n = 5. (C) Immunoblotting
for GRK5 in extracts from H9c2 cardiomyocytes, transfected with empty vector/mock lentivirus (EV),
full-length wild-type GRK5-encoding lentivirus to overexpress GRK5 (OE), CRISPR negative control
(mock) lentivirus (CNCV), or CRISPR rat GRK5-specific lentivirus to knockout GRK5 (KO). Total
protein extracts were prepared 48 h post-infection and then separated on a 4%–20% SDS-PAGE gel.
A representative blot is shown, including glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
as loading control, of five independent experiments performed in duplicate, confirming GRK5
overexpression and deletion in OE and KO cells, respectively. (D) Transcriptional activity of the MR in
response to various concentrations of Aldo in H9c2 cardiomyocytes overexpressing GRK5 (GRK5-OE)
or having GRK5 genetically deleted (GRK5-KO). EV: Empty vector; CNCV: CRISPR negative control
virus; * p < 0.05, between GRK5-KO and EV or CNCV; ** p < 0.05, between GRK5-OE and EV or CNCV;
n = 5 independent measurements with triplicate samples per Aldo concentration.
2.4. GRK5 Protects Against Aldo-Induced Apoptosis/Oxidative Stress and Is Necessary for Eplerenone’s
Inhibitory Actions in ARVMs
Since the cardiotoxic ffects f Aldo, including apopt sis, oxidative stress, fibrosis, and
inflammati n, are almost exclusively mediated by the MR [2,5], the finding that GRK5 phosphorylates
and inhibits the cardiac MR hints at potential cardioprotective effects of this kinase. Thus, we measured
the effects of GRK5 on Aldo signaling also in cultured adult rat ventricular myocytes (ARVMs),
a bona fide cardiomyocyte cell system even more physiologically relevant than H9c2 myocytes. We
also tested the effects of GRK5 in ARVMs in the presence or absence of the known MR antagonist
(MRA) drug eplerenone [17]. As shown in Figure 4A,B, eplerenone was only partially effective at
blocking Aldo-induced apoptosis in control ARVMs. In GRK5-overexpressing ARVMs however
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(Figure 4C), aldosterone’s efficiency at promoting apoptosis was significantly reduced compared to
control ARVMs and pretreatment with eplerenone resulted in complete abrogation of Aldo-induced
apoptosis (Figure 4A,B). Conversely, in ARVMs having GRK5 deleted via CRISPR/Cas9 (Figure 4C),
eplerenone was essentially incapable of blocking Aldo-stimulated apoptosis (Figure 4A,B). Similar
results were obtained when Aldo-dependent oxidative stress generation was measured in ARVMs
(Figure 4D). Indeed, GRK5 overexpression partially blocked Aldo-stimulated reactive oxygen species
(ROS) generation and enabled eplerenone to abolish it completely in ARVMs (Figure 4D), whereas,
in the absence of GRK5, this MRA was incapable of preventing Aldo-stimulated ROS generation in
ARVMs (Figure 4D). Taken together, these results indicate (a) that GRK5 inhibits Aldo-dependent
cardiac apoptosis and oxidative stress and (b) that GRK5 is essential for eplerenone’s cardioprotective
actions against these deleterious effects of Aldo in the myocardium.
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Figure 4. Effects of GRK5 in Aldo-induced apoptosis in adult rat ventricular myocytes (ARVMs):
(A,B) Apoptotic cell death, measured by terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL), in cultured ARVMs having GRK5 genetically (via CRISPR) deleted (GRK5-Del) or
overexpressing GRK5 (GRK5-OE) and treated with 100 n Aldo or 100 nM Aldo in the presence of
10 µM eplerenone (EPL + Aldo) for 24 hrs. rese tative i ages of EL-positive nuclei identified
by 4′,6-diamidino-2-phenylindole (DAPI) counterstaini g are shown in (A), and the quantitation of the
TUNEL imaging results are shown in (B). Control: CRISPR-negative co trol virus (CNCV)-infected cells.
* p < 0.05, vs. vehicle; #, p < 0.05, vs. Aldo; n = 5 independent experiments per tra sfection/treatment.
(C) Immunoblotting for GRK5 in extracts from cultured ARVMs, transfected with control empty
vector/mock lentivirus (Control), full-length wild-type GRK5-encoding lentivirus to overexpress GRK5
(OE), or CRISPR rat GRK5-specific lentivirus to delete the gene for GRK5 (Del). Total protein extracts
were prepared 48 h postinfection and then separated on a 4%–20% SDS-PAGE gel. A representative
blot is shown, including GAPDH as loading control, of five independent experiments performed
in duplicate, confirming GRK5 overexpression and deletion in OE and Del ARVMs, respectively.
(D) Reactive oxygen species (ROS) generation, as measured with a 2′,7′-dichlorofluorescein diacetate
(DCFDA)-based assay kit, in cultured ARVMs having GRK5 genetically (CRISPR-mediated) deleted
(GRK5-Del) or overexpressing GRK5 (GRK5-OE) and treated with 100 nM aldosterone (Aldo) or 100 nM
aldosterone in the presence of 10 µM eplerenone (EPL + Aldo) for 24 hrs. Results are expressed as
% of the fluorescence measured upon vehicle (DMSO) treatment for each cell clone. Control: Empty
vector/mock lentivirus-infected ARVMs. Eplerenone alone had no effect. * p < 0.05, vs. vehicle;
# p < 0.05, vs. Aldo; n = 6 independent experiments per transfection/treatment.
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2.5. MR Inhibition by GRK5 in ARVMs Is β2AR-Inducible
Our results from H9c2 cardiomyocytes indicated that β2AR activation augments the interaction
between GRK5 and the cardiac MR. On the other hand, GRK5 is activated by the β2AR (itself a
substrate of this kinase) [18]. Therefore, we sought to interrogate further the role of the β2AR in
GRK5-dependent MR inhibition in cultured ARVMs. As shown in Figure 5A,B, β2AR-selective
activation with salbutamol but not β1AR-selective activation with dobutamine significantly increased
the (Ser) phosphorylation of the endogenous MR. Of note, neither Aldo nor isoproterenol had any
appreciable effect on MR phosphorylation in ARVMs (Figure 5A,B), similarly to what was observed with
the GRK5–MR interaction in H9c2 cells (Figure 1). Importantly, β2AR-induced MR phosphorylation was
GRK5-mediated, since transient transfection of the ARVMs with a kinase-dead GRK5 (K215R) dominant
negative mutant [19] markedly suppressed basal and completely abrogated salbutamol-stimulated MR
phosphorylation in ARVMs (Figure 5C,D).
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Figure 5. β2AR stimulates the GRK5-dependent phosphorylation and inhibition of the cardiac MR.
(A,B) Immunoblotting for phosphoserine conte of the MR in response to 15-min-long treatments with
100 nM Aldo, 10 µM isoproterenol (Iso), 1 µM dobutamine (Dob), or 10 µM salbutamol (Salb) in ative
ARVM lysates. Representative blots are shown in (A), and the relative densitometric quantitation of five
independent experiments done in duplicate is shown in (B). * p < 0.05, vs. any other treatment; n = 5.
(C,D) Immunoblotting for phosphoserine content of the MR in response to 10 µM salbutamol (Salb) for
15 min or vehicle (DMSO) in ARVMs transfected with a GRK5 kinase-dead dominant negative mutant
(GRK5 KD) lentivirus or control, mock (empty vector, EV) lentivirus. Representative blots are shown in
(C), and the relative densitometric quantitation of six independent experiments done in duplicate is
shown in (D). * p < 0.05, vs. EV/−Salb; #, p < 0.05, vs. EV/+Salb; n = 6. IP: immunoprecipitation; IB:
Immunoblotting. (E) mRNA levels of plasminogen activator inhibitor (PAI)-1 in response to a 2-hr-long
treatment of 100 nM Aldo alone or in the presence of 10 µM salbutamol (Salb + Aldo) in ARVMs.
Lenti-GRK5 KD: Cells transfected with a GRK5 kinase-dead mutant lentivirus. 18S rRNA levels were
used for normalization of the results. NS: Not significant at p = 0.05; one-way ANOVA with Bonferroni
test; n = 6 independent experiments done in duplicate samples/condition.
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To confirm that β2AR-induced, GRK5-mediated MR phosphorylation leads to inhibition of
transcriptional activity also in ARVMs, we measured Aldo-dependent mRNA induction of the
plasminogen activator inhibitor (PAI)-1 gene, one of the immediate/early Aldo-inducible genes in
target tissues [20,21]. Indeed, β2AR activation with salbutamol completely blocked Aldo-induced
PAI-1 mRNA expression in ARVMs (Figure 5E). Importantly, this inhibitory effect of the β2AR was
GRK5-dependent, since salbutamol had no effect on Aldo-induced PAI-1 mRNA upregulation in
ARVMs transfected with the kinase-dead GRK5 mutant (Figure 5E). Taken together, these results
strongly suggest that the cardiac β2AR (but not the β1AR) induces GRK5-mediated phosphorylation
of the cardiac MR, thereby inhibiting the latter‘s transcriptional activity.
2.6. Cardiac β2AR-Stimulated GRK5-MR Interaction Is Cytoplasmic and Ca2+-Calmodulin (CaM)-Dependent
To delineate the signaling mechanism(s) underlying stimulation of GRK5-mediated
phosphorylation of the cardiac MR by the β2AR, we first examined the subcellular localization
of the GRK5–MR interaction in H9c2 cardiac myocytes. Since both the MR and GRK5 can localize in
both the cytoplasm and the nucleus [5,22,23], one important question arising from our present findings
is which subcellular fraction these two proteins interact with each other in. To this end, we subjected
H9c2 cell lysates to subcellular fractionation and we performed co-IP experiments in cytosolic and
nuclear fraction extracts. As shown in Figure 6A, the GRK5–MR complex could be detected only in the
cytosolic fraction extracts, both in the absence and presence of Aldo. Additionally, overexpression of a
dominant negative GRK5 mutant permanently “trapped” in the nucleus due to lack of a nuclear export
sequence (∆NES-GRK5) [23] was incapable of interacting with the MR in H9c2 whole cell lysates.
Therefore, GRK5 interacts with and phosphorylates the MR in the cytoplasm, causing retention of the
Aldo–MR complex in the cytosol, i.e., blockade of the complex‘s gene transcriptional activity.
Given that GRK5 is normally plasma membrane-anchored, thanks to its constitutive interaction
with membrane phospholipids [9], an important question pertains to the mechanism of its translocation
to the cytoplasm, wherein it phosphorylates the MR. Recent studies have revealed that the ubiquitous
Ca2+-binding protein CaM, known to inhibit GRK5 membrane localization and activity toward
GPCR phosphorylation [24], can markedly increase GRK5 activity towards non-GPCR (noncanonical)
substrates as well as can induce GRK5 translocation to the nucleus [22]. The latter process has been
reported to mediate GRK5-depedendent cardiac hypertrophy [23]. Therefore, we hypothesized that
Ca2+ signaling through CaM activation may be involved in the β2AR-stimulated GRK5–MR interaction
in the cytosol of H9c2 cardiomyocytes. Indeed, pretreatment of cells with the phospholipase C (PLC)-β
inhibitor U73122 [25] abolished the salbutamol-enhanced (but not the basal) GRK5 interaction with
the MR in H9c2 whole lysates (Figure 6B,C). Since PLCβ activation induces Ca2+ signaling and
activates CaM via Ca2+ release from intracellular 1’, 4’, 5’-inositol trisphosphate (IP3)-gated stores [26],
this result suggests that β2AR-activated GRK5 translocates to the cytosol to phosphorylate the MR in a
PLCβ-Ca2+-CaM-dependent manner.
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GRK5 translocation from the plasma membrane to the cytoplasm [22]. The MR has long been 
established as an important molecular culprit in heart disease progression [27]. In fact, the MR (but 
not the very closely related glucocorticoid receptor) was recently shown to promote cardiac 
dysfunction/cardiomyopathy, even without cardiac insult or injury, such as infarction or aortic 
constriction, in transgenic mice [28]. This suggests that all of the MR-dependent cardiac effects of 
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Figure 6. β2AR induces GRK5 translocation to the cytoplasm for subsequent MR phosphorylation.
(A) H9c2 cardiomyocytes were untreated or treated with 100 nM Aldo for 30 min. Subsequently, whole
cell protein lysates were prepared and subjected to subcellular fractionation. Cytosolic and nuclear
extracts fractions were separ tely immunoprecipitated (IP) with an a ti-MR antib dy, and the IPs
we e then immunoblotted (IB) for GRK5. Representative blots from six independent experiments are
shown, i cluding blots for MR to confirm equal amounts immunoprecipitated and for tubulin (cytosolic
marker) and lamin A (nuclear marker) to confirm the identity of the lysate fraction (cytoplasm or
nucleus, respectively). No GRK5 immunoreactivity could be detected in the MR IPs derived from the
nuclear lysates. (B,C) H9c2 cardiomyocytes were treated with 10 µM salbutamol (Salb) for 30 min in
the presence or absence of 10 µM U73122, and then, whole cell lysates were prepared to IP the MR,
followed by IB for GRK5. Representative blots are shown in (B), including blots for MR to confirm
equal amounts immunoprecipitated, and the relative densitometric quantitation of six independent
experiments done in duplicate is shown in (C). * p < 0.05; n = 6.
3. Discussion
In the present study, we have uncovered a new, noncanonical, and advantageous function of
cardiac GRK5: inhibitory phosphorylation of the MR (Figure 7). This GRK5 effect is β2AR-dependent
and proceeds through a noncanonical PLCβ-Ca2+-CaM signaling pathway (Figure 7), resulting in GRK5
translocation from the plasma membrane to the cytoplasm [22]. The MR has long been established as an
important molecular culprit in heart disease progression [27]. In fact, the MR (but not the very closely
related glucocorticoid receptor) was recently shown to promote cardiac dysfunction/cardiomyopathy,
even without cardiac insult or injury, such as infarction or aortic constriction, in transgenic mice [28].
This suggests that all of the MR-dependent cardiac effects of Aldo are harmful whereas the effects of
glucocorticoids, such as the endogenous glucocorticoid hormone cortisol, may actually be beneficial
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or protective for the myocardium. Indeed, there is vast array of studies over the past 15 years or so
confirming the deleterious role of the MR specifically in the heart and laying the mechanistic foundation
for the use of MRA drugs for the treatment of advanced human CHF [1,2,5,27].
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GRK2 and GPER inside cardiac myocytes. GRK5, activ ted by the cardiac β2AR vi PLCβ-Ca2+-CaM
signaling, translocates to the cytoplasm to phosphorylate the MR and inhibit its transcriptional activity
as a result of the Aldo–MR complex’s cytoplasmic-nuclear shuttling blockade. GRK2, on the other
hand, phosphorylates and desensitizes the agonist-activated GPER at the plasma membrane. Aldo:
Aldosterone; CA: Catecholamine; P: Phosphorylation; pSer: Phosphorylated serine; PLC: Phospholipase
C; PIP2: Phosphatidylinositol 4,5-bisphosphate; DAG: Diacylglycerol; IP3: Inositol 1,4,5-trisphosphate;
CaM: Calmodulin; ERK: Extracellular signal-regulated kinase. See text for more details and for all
other molecular acronyms’ descriptions. Solid arrows denote direct activation/action, dotted arrows
multi-step activation or translocation, and a denotes inhibition.
The MR undergoes various posttranslational modifications, such as phosphorylation, ubiquitination, etc.,
which regulate its transcriptional activity and/or ligand binding specificity/affinity [11,29]. Phosphorylation of
cofactors required for MR transcriptional activity plays a role as well [30]. GRKs are known to phosphorylate
not only agonist-activated GPCRs in order to desensitize them but also non-GPCR substrates [9,23]. GRK2
and GRK5 are the most abundant isoforms in extraretinal tissues, and GRK2, cytoplasmic when inactive,
requires interaction with the free Gβγ subunits of activated G proteins for activation/membrane
translocation [9]. In contrast, GRK5 is ionically bound to cell membrane phospholipids via a highly
basic region of its C-terminus, so it is usually cell membrane-anchored [31]. Notably, the MR was
recently shown to promote heart failure by activating GRK2-dependent apoptosis and GRK5 nuclear
accumulation-dependent hypertrophy in transgenic mouse hearts in vivo [30]. These noncanonical,
deleterious effects of the two GRKs were mediated by MR-induced, c-Src kinase-dependent cardiac
angiotensin II type 1 receptor (AT1R) transactivation [22,30].
In the present study, we have uncovered that these two GRKs can also regulate Aldo receptor
signaling in cardiac myocytes in their own right. Specifically, GRK5 (but not GRK2) phosphorylates
the MR in both H9c2 cardiomyocytes and in ARVMs, inhibiting its transcriptional activity, while GRK2
phosphorylates and desensitizes GPER (Figure 7). Moreover, this noncanonical effect of GRK5 is
β2AR-dependent. Moreover, it appears essential for the cardioprotection afforded by MRA drugs like
eplerenone against Aldo’s deleterious effects. Nevertheless, the precise effects of GRK5-dependent
Int. J. Mol. Sci. 2020, 21, 2868 11 of 17
MR phosphorylation on eplerenone’s MR inhibitory efficacy warrant further investigation and will
be the focus of our future studies. In addition, identification of the exact Ser/Thr residues of the
MR phosphorylated by GRK5 is already under way in our laboratory. An important question that
arises is why GRK2 appears incapable of phosphorylating the MR as GRK5 does. This awaits further
investigation. However, GRK5 phosphorylates the MR in the cytoplasm in order to block nuclear
translocation and subsequent gene transcription activation, and GRK2, when activated, is located in
the plasma membrane [9,23]. Thus, it is tempting to speculate that the reason might be simply the
different subcellular compartmentalization of active GRK2 and the MR that prevents their interaction.
Of note, GRK5’s nuclear/genomic effects, as a class II histone deacetylase (HDAC) kinase, have been
postulated to be harmful (i.e., pro-hypertrophic) in the heart [23]. Therefore, the subcellular localization
of GRK5 seems to be of paramount importance for this kinase‘s cardiac effects: inside the nucleus,
it promotes maladaptive hypertrophy, but in the cytoplasm, it has beneficial effects via inhibition of the
MR. Cardiac MR blockade is another line of evidence for GRK5’s overall beneficial, protective role
in the myocardium. Indeed, enhanced GRK5 activity has been associated with favorable, β-blocker
treatment-like outcomes in human CHF [32] with attenuated atherosclerosis [33] and with better cardiac
function in humans/CHF patients [34]. Additionally, GRK5 has been well documented to inhibit cardiac
nuclear factor (NF)-κB, resulting in reduced myocardial inflammation [35,36]. In contrast, every cardiac
effect of GRK2 reported thus far appears deleterious for cardiac function and/or structure [8,26], and our
present study adds one more to this list: cardiac GPER desensitization.
GPER (or GPR30) is a GPCR responsible for some of the rapid (non-genomic) effects of
estrogen [4,6,7]. It is expressed in both cardiac myocytes and fibroblasts and can couple to both
Gi and Gs proteins inducing EGFR or insulin-like growth factor-1 receptor (IGF-1R) transactivation
in various tissues [4,6,7]. The precise cardiovascular effects of GPER activation in the heart and in
vessels are still under intense investigation, but the majority of the studies indicate beneficial roles
for this receptor, such as vasodilation; antiapoptosis/proliferation of vascular smooth muscle and
endothelial cells; high-salt-induced diastolic dysfunction attenuation; reduction in left ventricular filling
pressure, mass, and wall thickness; improved cardiac function; and inhibition of cardiac fibroblast
proliferation [6,7]. Therefore, the fact that GRK2 opposes the antiapoptotic GPER signaling in cardiac
cells is consistent with this kinase’s well-established role in cardiac apoptosis and may represent
another mechanism underlying the cardiotoxic effects of this kinase [23].
As far as the signaling pathway that underlies the stimulation of GRK5 by the β2AR to
phosphorylate the cardiac MR in the cytoplasm is concerned, it is interesting to note that the β1AR
does not seem to share this ability. In fact, it probably opposes this GRK5 effect, since isoproterenol,
which activates both β2- and β1ARs equipotently, does not promote GRK5–MR association (Figure 1) or
MR phosphorylation by GRK5 (Figure 5A,B). The reason for this will be the focus of future investigations.
The obvious explanation would be that the β1AR cannot activate the PLCβ-Ca2+-CaM pathway as
the β2AR can and, thus, cannot induce the “shedding” of GRK5 from the cell membrane. In support
of this, a recent study reported that protein kinase A (PKA), robustly activated by the cardiac β1AR,
inhibits β2AR’s ability to stimulate Ca2+-CaM signaling via ERKs and IP3 in the caveolae of atrial
myocytes [37]. It is thus quite plausible that the β1AR antagonizes the β2AR-induced, Ca2+-dependent
GRK5 cytoplasmic/nuclear translocation in cardiac myocytes [22]. Of note, although it normally does
not couple to Gq proteins, the β2AR has been reported to directly activate PLCβ, eliciting intracellular
IP3-dependent Ca2+ mobilization/signaling [38].
4. Materials and Methods
All drugs/chemicals were from Sigma-Aldrich (St. Louis, MO, USA), except for Cmpd101
(HelloBio, Cat. #HB2840, Bristol, UK) and U73122 (MilliporeSigma, Cat. #CAS 112648-68-7, Burlington,
MA, USA).
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4.1. Cell Culture, Viruses, and Transfections
The H9c2 rat cardiomyoblast cell line was purchased from American Type Culture Collection
(Manassas, VA, USA) and cultured as previously described [12,39]. ARVMs were isolated from
adult male Wistar-Kyoto rats and cultured, as previously described [40]. H9c2 cells were used
because they are a universally accepted and widely used cell model system for signaling studies in
cardiac myocytes. Nevertheless, they are not bona fide cardiac myocytes (for instance, they do not
contract); for this reason, ARVMs, which are bona fide, fully differentiated cardiac myocytes, were also
used. Recombinant lentiviruses encoding for human wild-type full-length GRK5 or for empty vector
(control) (OriGene Technologies, Rockville, MD, USA) were propagated and purified via CsCl density
gradient ultracentrifugation, as described previously [25,39]. For CRISPR/Cas9-mediated GRK5 gene
deletion, a gRNA sequence was custom-synthesized by Sigma-Aldrich (target ID: RN0000391809,
target sequence: 5’-GTGGTTTGAATTTATGCGG-3’, predicted efficiency: 69.8, predicted specificity:
99.7) and incorporated into a lentiviral vector (Sigma-Aldrich). Along with negative control CRISPR
lentiviral particles (CNCV, Cat #CRISPR12V-1EA, Sigma-Aldrich), this lentivirus was also propagated
and purified through cesium chloride density gradient ultracentrifugation. The kinase-dead GRK5
(K215R) [19] mutant cDNA was generated using the QuikChange site-directed mutagenesis kit (Agilent
Technologies, Santa Clara, CA, USA), and proper insertion of the point mutation was verified by PCR.
The mutant cDNA was then inserted into a lentiviral vector for lentiviral particle production and
packaging (custom-made by Vigene Biosciences, Rockville, MD, USA).
4.2. Co-Immunoprecipitation (Co-IP) and Western Blotting
H9c2 or ARVM cell extracts were prepared, as described previously [39], in a 20-mM Tris pH 7.4
buffer containing 137 mM NaCl, 1% Nonidet P-40, 20% glycerol, 10 mM phenylmethylsulfonylfluoride
(PMSF), 1 mM Na3VO4, 10 mM NaF, 2.5 µg/mL aprotinin, and 2.5 µg/mL leupeptin. Protein
concentration was determined (Pierce BCA Protein Assay Kit, Thermo Scientific, Waltham, MA,
USA), and equal amounts of protein per sample were used for IP or western blotting. MR was
immunoprecipitated by overnight incubation of extracts with an anti-MR antibody (#ab62532; Abcam,
Cambridge, MA, USA), attached to Protein A/G-Sepharose beads (Sigma-Aldrich), while GPER
was immunoprecipitated with an anti-GPER antibody ((#ab39742; Abcam), also attached to Protein
A/G-Sepharose beads (Sigma-Aldrich). The IPs were then subjected to immunoblotting for GRK2
(sc-562; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or GRK5 (sc-565; Santa Cruz Biotechnology)
or for phosphoserine (AB1603; Millipore-Sigma) to measure the pSer content of the immunoprecipitated
MR. For the subcellular fractionation of H9c2 cells, cells were lysed using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Cat. #78833; Thermo-Scientific, Rockford, IL, USA), according
to the manufacturer’s instructions. Primary antibodies to detect tubulin (#ab56676; Abcam), as a
cytoplasmic fraction marker, and lamin A (#ab108922; Abcam), as a nuclear fraction marker, were used.
Finally, an anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (sc-25778; Santa Cruz
Biotechnology) was used to control for protein loading. All immunoblots were revealed by enhanced
chemiluminescence (ECL, Life Technologies, Grand Island, NY, USA) and visualized in the FluorChem
E Digital Darkroom (Protein Simple, San Jose, CA, USA), as described previously [39].
4.3. Luciferase Reporter Activity Assay
Luciferase reporter activity assay was performed by transfecting the cells with the LightSwitch™
luciferase reporter gene vector under the influence of the MR promoter (Active Motif, Inc., Carlsbad,
CA, USA) [41]. The measurements were done the next day with the manufacturer’s LightSwitch™
assay kit and according to its instructions.
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4.4. TUNEL and Real-Time PCR
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay to
measure apoptotic cell death was done as described [42]. Briefly, cells were fixed with 10% neutral
buffered formalin, embedded in paraffin, and sectioned at 5-µm thickness. DNA fragmentation
was detected in situ in deparaffinized sections using the ApopTag peroxidase in situ apoptosis
detection Kit (EMD Millipore) and according to manufacturer’s instructions. The total number of
nuclei was determined by manual counting of 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei
in six random fields per section. All terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL)-positive nuclei were counted in each section. Real-time PCR for rat PAI-1
mRNA levels in total RNA isolated from ARVMs was done as described previously [39,42,43]. Briefly,
quantitative real-time PCR was performed using a MyIQ Single-Color Real-Time PCR detection system
(Bio-Rad Laboratories, Hercules, CA, USA) using SYBR Green Supermix (Bio-Rad) and 100 nM of
gene-specific oligonucleotides. Quantification of mRNA included normalization to 18s rRNA levels.
No bands were seen in control reactions in the absence of reverse transcriptase. Primer pairs used
were 5’-TTCCTCCACAGCCATTCTAGTCT-3’ and 5’-GAAAGGATCGGTCTAAAACCATCTC-3’ for
PAI-1; 5′-TCGATGCTCTTAGCTGAGTG-3′ and 5′-TGATCGTCTTCGAACCTCC-3′ for 18S rRNA.
4.5. Oxidative Stress Assay
To determine reactive oxygen species (ROS) production, the 2′,7′-dichlorofluorescein diacetate
(DCFDA) dye-based assay kit from Molecular Probes (Cat. #C13293; Eugene, OR, USA) was
used, and the measurements were done according to manufacturer’s instructions and as previously
described [44]. Briefly, cell extracts were incubated with 2 µM DCFDA for 20 min and ROS production
was monitored by determining the fluorescence intensity using a fluorescent plate reader in which
excitation and emission wavelengths were set at 495 and 520 nm, respectively. The fluorescence OD
values obtained were normalized with protein determination and expressed as % of the values obtained
in vehicle (1 µM DMSO)-treated cells.
4.6. GTPγS Assay
The GTPγS assay was performed as we have previously described [45]. Briefly, cell membranes
were prepared by centrifugation and resuspension in hypotonic lysis buffer. The reaction was started by
adding an aliquot of membrane suspension to reaction buffer containing 25 mM Tris-HCl, pH 7.4, 5 mM
MgCl2, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol, 100 mM NaCl, 1 µM GDP,
and 2 nM [35S]-GTPγS (from PerkinElmer, Billerica, MA, USA) with or without agonist. Reaction was
stopped with ice-cold Tris-HCl buffer, pH 7.4, followed by filtration (Whatman GF/B glass fiber filters,
MilliporeSigma) and scintillation counting. Ten µM (cold) GTPγS was used to measure nonspecific
binding. Cells were pretreated with 100 nM G1 in the presence or absence of 30 µM Cmpd101,
followed by a 100 nM G1 challenge for 15 min in order to determine agonist-induced desensitization.
4.7. Statistical Analysis
Student’s t test and one- or two-way ANOVA with Bonferroni test were used for statistical
comparisons, unless otherwise indicated. For multiple group analyses, Dunnett’s test with SAS version
9 software (Cary, NC, USA) was also used. A p value of <0.05 indicated statistical significance.
5. Conclusions
We have uncovered a new unconventional (non-GPCR) substrate for cardiac GRK5, the MR,
which results in cardioprotective effects of this kinase against Aldo. In contrast, GRK2 phosphorylates
and desensitizes cardiac GPER with potentially cardiotoxic consequences. Admittedly, the major
limitation of our study is that its findings await in vivo validation. Nevertheless, we have confirmed
this novel role for cardiac GRK5 in a bona fide cardiomyocyte cell system (ARVMs) and we have
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delineated the underlying signaling mechanism. Upon confirmation in vivo, these findings may
provide additional evidence for the emerging role of GRK5 as the GRK isoform acting as the protective
ballast against the generally deleterious GRK2 in the heart. Finally, GRK5-dependent MR inhibition
appears essential for the cardioprotection afforded by MRA drugs, like eplerenone, against Aldo. Given
the problems and limitations hampering clinical efficacy of this drug class for advanced human CHF
and other heart diseases [5], cardiac GRK5 stimulation (either directly with a small organic molecule or
indirectly via β2AR-selective agonism) may offer a new pharmacotherapeutic avenue to augment the
cardiac benefits of Aldo inhibitor drugs.
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GPCR G protein-coupled receptor
GRK G protein-coupled receptor-kinase
GPER G protein-coupled estrogen receptor
CHF Chronic heart failure
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TUNEL Terminal deoxynucleotidyl transferase dUTP nick-end labeling
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EGFR Epidermal growth factor receptor
IGF-1R Insulin-like growth factor-1 receptor
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